Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases, founded back in 2015. At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumors and hematologic malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.Harpoon generates $144.4K in revenue per employee Harpoon has received a total of $223.2M in funding. Harpoon's top competitor is TCR2, led by Garry E. Menzel, who is their President & CEO. Harpoon is seeking energetic, passionate scientists and innovators to join in effort. Harpoon Therapeutics offers a dynamic, diverse and state-of-the-art work environment in South San Francisco
Similar companies
